NCT06522919 - Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 7, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

September 1, 2026

Conditions

Colorectal Cancer MetastaticMicrosatellite Stable Colorectal CarcinomaRefractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer

Interventions

BIOLOGICAL

Autologous Dendritic Cell (DC) Vaccine

Induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a maintenance chemotherapy (FTD/TPI plus Bevacizumab) in patients with refractory MSS/pMMR metastatic colorectal cancer.

Trial Locations (2)

47014

RECRUITING

"IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori-IRST S.r.l.", Meldola

73039

NOT_YET_RECRUITING

"Pia Fondazione di Culto e Religione Azienda Ospedaliera Card.G.Panico", Tricase

All Listed Sponsors

lead

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

OTHER